ExploreWatchlistsPricing
  1. JP-listed companies
  2. D.Western Therapeutics Institute, Inc.
  3. Financials
  4. Operating income

D.Western Therapeutics Institute, Inc. (4576)

Market cap
¥5.2B
P/E ratio
-6.4x
De Western Therapeutics Institute develops protein kinase inhibitor drugs for eye diseases and licenses them to pharmaceutical companies for commercialization.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndOperating income (Million JPY)YoY (%)
Dec 31, 2025-620-48.75%
Dec 31, 2024-1,210+51.47%
Dec 31, 2023-799+161.04%
Dec 31, 2022-306+78.22%
Dec 31, 2021-172-35.39%
Dec 31, 2020-266-326.47%
Dec 31, 2019117-114.92%
Dec 31, 2018-786+24.08%
Dec 31, 2017-634+98.21%
Dec 31, 2016-320+10.05%
Dec 31, 2015-291+47.51%
Dec 31, 2014-197

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat